Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Rhea-AI Summary

Mirum Pharmaceuticals, a biopharmaceutical company specializing in rare and orphan diseases, is set to present at the Citizens JMP Life Sciences Conference in New York on May 14th. Investors can access the webcast via Mirum's website.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Citizens JMP Life Sciences Conference in New York, NY on Tuesday, May 14^th at 1:30 PM EDT.

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. Mirum has submitted for approval in Europe for the treatment of PFIC in patients two months of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240507489492/en/

Investor Contact:

Andrew McKibben

investors@mirumpharma.com

Media Contact:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When is Mirum Pharmaceuticals presenting at the Citizens JMP Life Sciences Conference?

Mirum Pharmaceuticals will present at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 1:30 PM EDT.

Where is the Citizens JMP Life Sciences Conference taking place?

The Citizens JMP Life Sciences Conference is happening in New York, NY.

How can investors access the webcast of Mirum Pharmaceuticals' presentation?

Investors can access the webcast through the Investors and Media section of Mirum's corporate website.